SLC5A2 and atrial fibrillation: Specifically, the glucose‐lowering targets KCNJ11/ABCC8 (sulfonylureas), SLC5A2 (SGLT2i), and RXRB (TZDs) were associated with a decreased risk of PT, AF and RBBB, respectively.